Supplementary Material for: Use of Next Generation Sequencing for Highly Endocrine-Sensiti

Supplementary Material for a case report details the use of next-generation sequencing (NGS) to inform targeted therapy in a patient with highly endocrine-sensitive metastatic breast cancer. The dataset, a 1.2 MB PDF authored by a figshare admin for Karger, was last updated on April 21, 2026. It describes the discovery of mutations in PIK3CA, ESR1, NRG1, and KRAS over a 15-year disease course.

Use Cases

• Study the temporal emergence of actionable mutations like PIK3CA and ESR1 based on the described longitudinal NGS testing.
• Analyze the clinical trajectory of metastatic breast cancer based on the detailed 15-year case history.
• Investigate the role of rare genomic alterations, such as NRG1 NTRK fusions, in late-stage breast cancer based on the case findings.

Strengths

• Dataset is openly licensed under CC-BY-4.0.
• Provides a detailed longitudinal clinical and genomic history over a 15-year period as described in the case report.

Limitations

• Row count and column-level documentation are unknown, which may limit suitability assessment.
• The dataset is a single 1.2 MB PDF, suggesting a small-scale, narrative case report rather than a structured data table.

Provenance

Source

figshare admin karger

Collection Method

Likely contains clinical and genomic data from a single patient case study.

Time Range

Covers a patient's disease course over approximately 15 years of metastatic treatment.

Freshness

Last updated 2026-04-21 03:55:14.